Dianthus Therapeutics to Host Conference Call and Webcast to Discuss the Interim Responder Analysis Results of the Phase 3 Captivate Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Rhea-AI Summary

Dianthus Therapeutics (Nasdaq: DNTH) will host a conference call and webcast on March 9, 2026 at 8:00 a.m. ET to discuss interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.

Live access is available by phone with pre-registration and via the investor webcast at https://investor.dianthustx.com/. A replay will be posted following the call.

News Market Reaction – DNTH

+21.52%

10 alerts

+21.52% News Effect

+10.3% Peak Tracked

-3.5% Trough Tracked

+$602M Valuation Impact

$3.40B Market Cap

0.0x Rel. Volume

On the day this news was published, DNTH gained 21.52%, reflecting a significant positive market reaction. Argus tracked a peak move of +10.3% during that session. Argus tracked a trough of -3.5% from its starting point during tracking. Our momentum scanner triggered 10 alerts that day, indicating notable trading interest and price volatility. This price movement added approximately $602M to the company's valuation, bringing the market cap to $3.40B at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

Conference call time: 8:00 a.m. ET Trial phase: Phase 3

2 metrics

Conference call time 8:00 a.m. ET Scheduled for March 9, 2026 to discuss interim responder analysis

Trial phase Phase 3 CAPTIVATE trial of claseprubart in CIDP, Part A interim analysis

Market Reality Check

Price: $85.84 Vol: Volume 1,075,186 is 1.53x...

high vol

$85.84 Last Close

Volume Volume 1,075,186 is 1.53x the 20-day average of 704,419, indicating elevated interest ahead of the call. high

Technical Price $65.04 is trading above the 200-day MA of $33.94 and near the 52-week high of $65.50.

Peers on Argus

DNTH is up 6.14% with elevated volume, while only one peer (e.g., ZYME in moment...

1 Up

DNTH is up 6.14% with elevated volume, while only one peer (e.g., ZYME in momentum scanner up 3.20%) shows upside activity, pointing to a stock-specific move.

Previous Conferences,clinical trial Reports

1 past event · Latest: Sep 07 (Neutral)

Same Type Pattern 1 events

Date	Event	Sentiment	Move	Catalyst
Sep 07	Conference clinical update	Neutral	+20.0%	Announced call to discuss Phase 2 MaGic trial results for claseprubart.

Pattern Detected

Prior similar conference/clinical calls for claseprubart coincided with a notable positive price reaction.

Recent Company History

Recent news flow for Dianthus has emphasized investor outreach and clinical development. A prior same-tag event on Sep 7, 2025 announced a conference call to discuss Phase 2 MaGic trial results for claseprubart in gMG and saw a 20% move. Today’s Phase 3 CAPTIVATE CIDP interim responder analysis call continues this pattern of using webcasts to highlight key data milestones to investors.

Historical Comparison

+20.0% avg move · Past conference+clinical updates for claseprubart produced an average 20% move, framing expectations...

conferences,clinical trial

+20.0%

Average Historical Move conferences,clinical trial

Past conference+clinical updates for claseprubart produced an average 20% move, framing expectations around this Phase 3 CAPTIVATE interim call.

The company has progressed from a Phase 2 MaGic trial update in gMG to a Phase 3 CAPTIVATE interim responder analysis in CIDP, both highlighted via investor conference calls.

Regulatory & Risk Context

Active S-3 Shelf · $600,000,000

Shelf Active

Active S-3 Shelf Registration 2026-01-28

$600,000,000 registered capacity

An effective S-3 shelf filed on 2026-01-28 allows Dianthus to issue up to $600,000,000 of various securities over time, primarily to fund clinical and corporate needs. No usage has been reported yet, but the capacity enables future capital raises that could affect existing shareholders.

Market Pulse Summary

The stock surged +21.5% in the session following this news. A strong positive reaction aligns with p...

Analysis

The stock surged +21.5% in the session following this news. A strong positive reaction aligns with prior same-tag events, where a claseprubart conference-and-clinical update produced a 20% move. Trading above the 200-day MA and near the 52-week high suggests optimism around the CAPTIVATE interim responder analysis. However, an effective $600,000,000 shelf provides ample capacity for future offerings, which could temper extended gains if utilized.

Key Terms

chronic inflammatory demyelinating polyneuropathy, cidp, phase 3

3 terms

chronic inflammatory demyelinating polyneuropathy medical

"Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)"

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long‑term autoimmune disorder in which the body attacks the protective coating (myelin) around peripheral nerves, causing progressive weakness, numbness and poor coordination. Think of myelin as insulation on electrical wires: when it is damaged, nerve signals slow or fail. CIDP matters to investors because it drives demand for ongoing medical treatments, costly therapies and clinical trials, and outcomes or approvals can significantly affect companies developing drugs or devices for the disease.

cidp medical

"claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow"

Chronic inflammatory demyelinating polyneuropathy (CIDP) is a long‑term autoimmune disorder in which the immune system progressively damages the protective coating (myelin) around peripheral nerves, causing weakness, numbness and reduced coordination — like frayed insulation on electrical wiring that disrupts signal flow. It matters to investors because treatments, clinical trial results, regulatory approvals and reimbursement decisions directly affect demand, pricing and revenue prospects for companies developing therapies for this disabling condition.

phase 3 medical

"interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial"

Phase 3 is the late-stage clinical testing step for a new drug or medical treatment, where the product is given to large groups of patients to confirm effectiveness, monitor side effects, and compare it to standard care. Successful Phase 3 results are often the final scientific hurdle before regulators decide on approval and market launch—like passing a final exam before graduation—and can sharply change a company's valuation and future revenue prospects.

AI-generated analysis. Not financial advice.

NEW YORK and WALTHAM, Mass., March 08, 2026 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases, today announced a conference call and webcast to discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) scheduled for tomorrow, Monday, March 9, 2026 at 8:00 a.m. ET.

Investor Conference Call & Webcast Information
To access the live conference call by phone, please register here. Conference call participants in the question and answer session should pre-register to receive the dial-in number and personal PIN. 

The live webcast may be accessed via the Investors section of the Dianthus Therapeutics website at https://investor.dianthustx.com/. A replay of the webcast will be available following the call.

About Dianthus Therapeutics
Dianthus Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing next-generation therapies to transform the treatment of severe autoimmune diseases. Based in New York City and Waltham, Mass., Dianthus is comprised of an experienced team of biotech and pharma executives who aim to deliver transformative medicines for people living with severe autoimmune and inflammatory diseases.

To learn more, please visit www.dianthustx.com and follow us on LinkedIn. 

Contact
Jennifer Davis Ruff
Dianthus Therapeutics
jdavisruff@dianthustx.com

FAQ

When is the Dianthus (DNTH) conference call to discuss CAPTIVATE interim results?

The conference call is scheduled for March 9, 2026 at 8:00 a.m. ET. According to the company, the call will review interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial of claseprubart in CIDP.

How can investors access the DNTH March 9, 2026 webcast and replay?

Investors can access the live webcast via the Dianthus investor website at the provided URL. According to the company, a replay of the webcast will be available on the investor site after the conference call concludes.

Do I need to register to join the Dianthus (DNTH) investor conference call by phone?

Yes, phone participants must pre-register to receive a dial-in number and personal PIN. According to the company, registration is required for the question-and-answer session and access to the live phone line.

What will Dianthus (DNTH) discuss during the March 9, 2026 CAPTIVATE call?

The company will discuss the interim responder analysis results from Part A of the Phase 3 CAPTIVATE trial. According to the company, the presentation will focus on responder data for claseprubart in patients with CIDP.

Where can I find materials or slides from the DNTH CAPTIVATE interim results call?

Presentation materials and any supplemental disclosures are typically posted on the investor relations website. According to the company, investors should check the Dianthus investor site for slides, replays, and related documents after the call.